Cargando…
Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function
BACKGROUND: Risk evaluation and mitigation strategies (REMS), as mandated by the US Food and Drug Administration (FDA) for medications with the potential for harm, are increasingly incorporating rigid protocols for patient evaluation, but little is known about compliance with these programs. Despite...
Autores principales: | Blanchette, Christopher M, Nunes, Anthony P, Lin, Nancy D, Mortimer, Kathleen M, Noone, Joshua, Tangirala, Krishna, Johnston, Stephen, Gutierrez, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Just Medical Media Limited
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335780/ https://www.ncbi.nlm.nih.gov/pubmed/25709706 http://dx.doi.org/10.7573/dic.212272 |
Ejemplares similares
-
Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
por: Brandenburg, Nancy A., et al.
Publicado: (2017) -
Implications of Risk Evaluation and Mitigation Strategy (REMS) Programs for Managed Care Pharmacy
por: Projects, AMCP Special
Publicado: (2012) -
Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products
por: Pergolizzi, Joseph V, et al.
Publicado: (2013) -
The Xyrem(®) (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
por: Strunc, Michael J., et al.
Publicado: (2021) -
Structural differences between REM and non-REM dream reports assessed by graph analysis
por: Martin, Joshua M., et al.
Publicado: (2020)